NAIC Consumer Representative Carl Schmid speaks at the 2023 NAIC Spring Meeting on a panel about how insurers create barriers to prescription drugs through onerous prior-authorization requirements.

NAIC Consumer Representative Carl Schmid speaks at the 2023 NAIC Spring Meeting on a panel about how insurers create barriers to prescription drugs through onerous prior-authorization requirements.
Carl Schmid discusses discrimination in prescription drug formularies, demonstrating how some PBMs and private insurers violate ACA provisions and hurt patients by placing life-saving prescription drugs on higher cost tiers.
Carl Schmid, along w/ other NAIC consumer reps., provides federal update at its Fall Meeting in Tampa with a focus on updated regulations to strengthen ACA Section 1557 non-discrimination rule and copay accumulator litigation to ensure copay assistance counts.
At Informa Connect’s Copay, Reimbursement and Access Congress, Carl Schmid discusses the litigation filed by HIV+Hep, the DLC, and the DPAC in the U.S. District Court for DC challenging a federal rule that allows health insurers to avoid counting the value of drug manufacturer copay assistance toward patients’ out-of-pocket cost obligations in violation of the ACA definition of and regulations for cost-sharing.
Carl Schmid discusses on a National Consumers League webinar current federal advocacy efforts to ensure that copay assistance for prescription drugs counts. This includes comments on two regulations, a congressional bill, and recent litigation initiated by HIV+Hep and two diabetes groups.